The clinical efficacy of MLN0128 in this form of PCa was limited due to drug toxicity, an increase in PSA levels suggesting hormone reactivation resulting from mTOR inhibition, and the poor inhibition of mTOR signaling targets. This evidence concerns the gene MTOR and posterior cortical atrophy.